Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.60 - $16.62
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.15M
Market Cap
$344.40M
Enterprise Value$470.65M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 03, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding68,333,060
10 Day Avg. Volume804,067
30 Day Avg. Volume1,154,620
Standard Deviation0.28
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.25K
Enterprise Value/Ebitda-3.47
Forecast
1Y Price Target
$27.80Price Target Upside447.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Pharmaceuticals Advances in Cancer Therapy Development
PremiumCompany Announcements
Olema Pharmaceuticals Advances Breast Cancer Treatments
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of palazestrant and ribociclib is advancing into a Phase 3 study, suggesting promising progress in clinical trials.
Market PositionNovartis included ribociclib + palazestrant within their selected oncology pipeline, indicating potential recognition and validation of Olema's drug combination.
PartnershipThe expanded clinical collaboration and supply agreement with Novartis reflects confidence in the potential of palazestrant + ribociclib for advanced ER+ breast cancer treatment.
Bears Say
Financial ConcernsOlema has an annualized cash burn of $108 million.
Monotherapy LimitationsImlunestrant is only effective as a monotherapy in ESR1m patients and not in wild-type patients.
Safety ConcernsThe safety profile of the combo appeared well tolerated with most common adverse effects being diarrhea, neutropenia, nausea, and fatigue.
---
Ownership Overview
21.51% Insiders
8.82% Mutual Funds
0.31% Other Institutional Investors
60.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $4.60 and its highest was $16.62 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $344.40M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 03, 2025 which is in 10 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.571 by -$0.029.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.64.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 68,333,060 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.571. Following the earnings report the stock price went down -0.52%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
---
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.80 (447.24% Upside)
$27.80 (447.24% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 319.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.57%
12-Months-Change
Fundamentals
Return on Equity
-51.76%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$27.80
▲(447.24% Upside)
Technical Analysis
Fate Therapeutics
―
Kura Oncology
―
Scholar Rock Holding
―
IGM Biosciences
―
ALX Oncology Holdings
―
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+63.66%
assigned a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +63.66% per trade.
---